Kaposi sarcoma is caused due to the infection of a virus called as Kaposi sarcoma associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma such as AIDS-KS, immunocompromised, classic or sporadic and endemic. Technological advancement in the drug delivery such as targeted immunotherapy and nanomedicines are utilized to facilitate the cytotoxic payload through the blood vessels in the Kaposi sarcoma tumors which usually develops from the cells that line the lymph or blood vessels.

For the purpose of this study, the global Kaposi sarcoma market is studied in terms of treatment types and geography. The drug classes studied in the report includes chemotherapy which is further categorized as (alkaloids and liposomal anthracyclines), immunotherapy, HAART, radiation therapy and surgical procedures. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global Kaposi sarcoma market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global Kaposi sarcoma market. The key players profiled in this report are Aphios Corp, Cytori Therapeutics, Inc., Bristol Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc.

The Kaposi sarcoma market is driven by factors such as rising prevalence of AIDs related Kaposi sarcoma, increasing number of iatrogenically immunocompromised patients and urgent requirement for novel drug discovery in treating subtypes such as classic Kaposi sarcoma found in the Eastern Mediterranean region. In addition, increasing number of diagnostic centers and increasing physician awareness regarding disease etiology will propel the deep market penetration for Kaposi sarcoma. In 2016, highly active antiretroviral therapy (HAART) segment held the largest market share due to factors such as rising prevalence of AIDS, as patients suffering with HIV infection are prone to develop Kaposi sarcoma etiology and the proactive government initiative such as United States Presidents Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS.

Chemotherapy will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as technological advancement in the drug formulation for e.g. paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS surpassing the drug biotransformation which is toxic to liver cells. Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes acid sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues. The major players in kaposi sarcoma market are Aphios Corp, Cytori Therapeutics, Inc., Bristol Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc.

North America was observed to be the largest market for kaposi sarcoma in the base year 2016. According to the American Cancer Society in 2016 the occurrence rate of kaposi sarcoma was 6 cases per million people. More prevalent in the Afro-American men. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of AIDS-KS, affordable reimbursement scenario and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the presence of major pharmaceutical players involved in kaposi sarcoma research and rising public health awareness resulting into early disease diagnosis and treatment. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are increasing number of AIDS patients with kaposi sarcoma complications, increasing disposable incomes and supportive regulatory environment for kaposi sarcoma drug products. Moreover, factors such as developing health infrastructure and proactive government initiatives to fight AIDS-KS in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of kaposi sarcoma market in Latin America, and Middle East and Africa in the near future.   

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Kaposi Sarcoma market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Kaposi Sarcoma market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Kaposi Sarcoma market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Kaposi Sarcoma market?
• Which is the largest regional market for Kaposi Sarcoma market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Kaposi Sarcoma market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Kaposi Sarcoma market worldwide?